Novo Nordisk on Tuesday reported that its experimental obesity drug CagriSema produced an average 25% weight loss in adult women in a post-trial analysis, offering fresh evidence that the combination of semaglutide and cagrilintide may provide a powerful tool for weight management, particularly during menopause.
company
Novo Nordisk
Danish pharmaceutical company